徐国彤 教授
硕士招生类型：学术型
硕士招生专业：药学、眼科学
博士招生类型：学术型
博士招生专业：基础医学、眼科学
所在院系：医学院
联系方式：gtxu@tongji.edu.cn
课题组链接：https://mednew.tongji.edu.cn/ktz/Group.aspx?id=18
研究方向
主要任职
科研业绩

老年性眼病发病机理和创新治疗方法研究。具体包括：（1）糖尿病视网膜病变发病机制和治疗方法；（2）视网膜变性发病机制及干细胞治疗研究；（3）老年性白内障和衰老的发生机制以及抗白内障抗衰老药物研发。
Our research interests are focused on the pathogenesis and innovative treatments of age-related eye diseases. It includes 3 major projects: (1) the pathogenesis and treatment of diabetic retinopathy; (2) the pathogenesis and stem cell-based therapies of retinal degeneration; (3) the mechanism of age-related cataract as a model of aging, and the development of anti-cataract and anti-aging drugs.
主要任职：同济大学****、同济大学新生院济人学堂执行院长、同济大学医学眼科研究所所长、华东干细胞库主任、同济大学附属第十人民医院（眼科）首席科学专家。
社会兼职主要包括：中国细胞生物学学会干细胞生物学分会首任会长、理事；中国医师协会眼科分会基础研究与临床转化专委会主委、海医会眼科分会常委及干细胞学组组长、中俄眼科大学联盟眼科分会常委、上海市医学会眼科专科分会视觉研究学组组长、上海市药学会理事及药理专业委员会副主任委员等。担任Curr Mol Med、《中华细胞与干细胞杂志》等杂志副主编。
Main positions: Distinguished Professor of Tongji University, Executive Director of Jiren school, freshman college of Tongji University, Director of Tongji Eye Institute of Tongji University School of Medicine, Director of East China Stem Cell Bank, Chief Scientific Expert of the Tenth People
长期从事老年性眼病转化医学研究。特别聚焦在糖尿病视网膜病变（糖网病）、黄斑变性和白内障的发病机制和创新治疗方法研究。在白内障研究中，晶状体的变化不仅影响患者视力，更有意义的是代表着机体组织器官的衰老过程，是研究衰老的理想的模型。阐明年龄相关性白内障的发病机制，有助于研发治疗白内障的药物并可能有助于干预机体衰老。我们课题组先后阐明了萘白内障的发病机制、Vimentin在晶体发育和白内障形成中的表观调节机制、吸烟与白内障的关系及机制等，为研发抗白内障甚至抗衰老药物指出新靶点。在糖网病研究中，在国际上首次研发出EPO眼内注射治疗糖网病的方法，已完成药效、药代、毒理、作用机制等研究并在美国的初步临床试验中获得满意疗效，发表的系列论文广受重视，并申请了中、美、加、欧、日、澳的发明专利。关于EPO治疗机制的研究被《Review of Ophthalmology》点评为2010年糖网病研究三项重要进展之一，标志着这项工作的国际领先水平。目前正在研发基于EPO的糖网病的基因治疗。在视网膜变性研究中，利用干细胞开展治疗视网膜变性研究取得重要进展。在骨髓间充质干细胞（MSCs）和脂肪干细胞（ADSCs）移植治疗视网膜变性的大鼠模型研究中获得了满意结果，通过MSC亚型的选择优化以及用EPO基因修饰MSCs的方法治疗视网膜变性，取得了更理想的疗效。在胚胎干细胞来源供体细胞的成瘤性研究中，发现其成瘤性与Wnt信号通路密 切相关，通过抑制该通路能成功使成瘤性从约60%降低到3%，并阐明了成瘤机制和抑瘤药物作用机理，2013年在国际著名医学杂志JCI发表时被选为封面论文及配有专家正面评述。高效诱导iPS细胞分化为视网膜祖细胞即RPE细胞的工作将传统需要120-150天的工作用明确的化学成分和处理时间提高到25天，并且在动物模型中干预效果良好。研究中发现了GMFB在糖尿病发病早期组织器官损伤的病理过程中的作用，可能会成为糖尿病并发症的早期标记物和新的治疗的靶点，相关论文和专利等构成的研究成果在2019年日内瓦发明展中获银奖。
在干细胞研究领域，2007年和2013年两次担任科技部973重大科学研究计划首席科学家以来，牵头建立了科技部项目干细胞库网络并担任华东干细胞库主任；组织成立了中国细胞生物学会干细胞生物学分会并担任首任会长；建立了中国干细胞网站；与国内主要专家推动成立了“国家干细胞与再生医学产业技术创新战略联盟”并任理事；组织启动了 “中国干细胞研究年会”制并主办了首届年会，现已持续九届，成为国内干细胞界规模最大水平最高的系列性年度学术会议；担任《中华细胞与干细胞杂志》副主编；已主办干细胞高级培训班约50次，累计培训学员500余人次；积极参与起草有关干细胞研究与应用管理的活动和文件。研究内容，除利用干细胞治疗视网膜变性和皮肤疾患外，近年来加强了在干细胞衰老和利用干细胞抗衰老研究。
我们团队先后承担国家级科研项目十余项，包括两次973重大科学研究计划首席科学家和一次重大国际合作项目共同首席科学家。已发表SCI论文约百篇，被引用逾千次；出版专著/教材5本；申请并获得授权的发明专利近10余项。
Key Research Work:My team’s research focuses on
(1) stem cell-based therapy and gene therapy
(2) age-related eye diseases (mainly age-related macular degeneration or AMD, and diabetic retinopathy or DR)
(3) aging and anti-aging (focusing on cataract study and anti-cataract drugs development).
A few interesting projects and progresses are briefly listed below:
（1）We developed of a new therapy for diabetic retinopathy, the intravitreal injection of EPO. Our studies proved that EPO in the eye protected retina during DR, and further explained the pathology of DR and revealed the mechanism of EPO in its intervention of DR. Phase Ia clinical Trail has been completed in the States, in collaboration with Dr. Sinclair and Dr. Li. It is a milestone in understanding and treating DR since EPO was previously considered as a key factor facilitating the development of DR. Now, we are further focusing on DR pathogenesis and developing an EPO gene therapy for DR. In addition, the factor GMFB has been proved to be a marker for early diabetes and potential new target for treating DR and other diabetic complications. Our articles and patents on this study won a silver prize at the 2019 Geneva International Invention Fair.
（2）Cataract development is a process of aging. We are trying to understand why it happens and how to delay its progress. Using naphthalene-induced cataract as a model, we revealed, at least part of, its mechanism, and clarified its relationship with sugar cataracts. Now, we are screening anti-naphthalene cataract drugs and some results are promising.
（3）In stem cell research, we provided more and better understanding of the mechanism of the tumorigenicity and therapeutic effects of the transplanted embryonic stem cells-derived retinal progenitor cells (JCI cover story), and developed more effective interventions of retinal degeneration with adult stem cells like bone marrow mesenchymal stem cells and adipose-derived stem cells. We are filing a patent for a new method by which people could reduced the time from 120-150 days to 18-25 days when iPS cells were induced to differentiate into RPE cells.
（4）We established the East China Stem Cell Bank and developed the China Stem Cell Bank network with other 3 teams under the support of a China National Major Research Program (973 program), initiated the Chinese Society for Stem Cell Biology (and served as the founding president), and initiated the annual meeting system of Chinese Stem Cell Research (and organized the first meeting in Shanghai as the chairman). The ongoing work focuses on the translational research on stem cell-based therapy for retinal degeneration like AMD.
By now, our team has undertaken more than ten national scientific research projects, including two chief scientists of 973 major scientific research projects and one co-chief scientist of a major international cooperation project of MOST. We have published about 100 SCI papers, which are cited more than 1,000 times. We also published 5 monographs/textbooks in ophthalmology and stem cell research. More than 10 invention patents we applied have been authorized.